Furosemide API pricing in the United States has evolved substantially over the past five years, shaped by supply chain diversification away from China, FDA import alert cycles affecting specific facilities, and structural cost pressures on regulated-market API supply. For US pharmaceutical procurement teams supporting ANDA-registered furosemide finished-dose products, understanding the drivers of US Furosemide API pricing is essential to procurement planning and supplier negotiation. This analysis covers the current pricing landscape and what US buyers should expect when sourcing a furosemide API supplier for export into the US market.
The analysis draws on general Indian API export pricing patterns, publicly available FDA regulatory action data, and the structural cost differentials between Indian, Chinese, and European Furosemide API sources. Specific per-kilogram pricing is not published in this article, as commercial pricing varies significantly by order volume, pharmacopoeial grade, regulatory documentation package, and delivery terms. Contact Kodel Life directly at info@kodellife.com or call +91 75023 33335 for current USA-specific commercial quotations.
The US Furosemide API Market: Structural Overview
The United States is one of the largest global markets for Furosemide finished-dose products, with the American Heart Association estimating that approximately 6.7 million US adults live with heart failure — the primary chronic indication for Furosemide therapy. Multiple ANDA approvals are active for Furosemide tablet and injection formulations, distributed across generic manufacturers who source their drug substance from a mix of Indian, Chinese, and European API producers with active US FDA Type II Drug Master Files.
The API sourcing landscape for US ANDA holders operates under distinct constraints compared to semi-regulated market sourcing. Every commercial Furosemide API supplier serving the US must maintain an active DMF referenceable by the ANDA holder, FDA inspection standing without active import alerts, and process documentation meeting FDA's Data Integrity requirements. These constraints eliminate a significant portion of the global Furosemide API supplier base from US supply consideration, concentrating demand on a smaller pool of qualified DMF-filed manufacturers whose pricing reflects the compliance investment required to maintain US regulatory eligibility.
Six Factors Driving Furosemide API Pricing in the USA (2026)
1. DMF Compliance Cost Premium
Furosemide API destined for US ANDA support carries a structural pricing premium over material sold into semi-regulated markets. The premium reflects the manufacturer's ongoing investment in DMF maintenance, annual DMF fees paid to FDA under the GDUFA framework, FDA inspection preparation and response costs, and the incremental documentation depth required for US market compliance. The compliance cost is amortised across the manufacturer's US-directed sales volume, producing a per-kilogram premium of approximately 15 to 25 percent above equivalent semi-regulated market pricing for the same molecule from the same facility.
2. Indian vs Chinese API Source Cost Differential
Historically, Chinese Furosemide API pricing was 10 to 20 percent below Indian equivalent grades due to lower manufacturing input costs. This differential has compressed over 2020 to 2025 as Chinese labour costs increased, environmental compliance costs rose, and API supply chain concentration risks associated with China became apparent to US procurement teams following the pandemic-era supply disruptions. As of 2026, the Indian versus Chinese Furosemide API pricing gap is significantly narrower than five years ago, and Indian manufacturers with active US DMFs and clean FDA inspection records have gained proportional US market share.
US buyers evaluating the regulatory documentation depth that supports a DMF-filed Furosemide API supplier's US market pricing premium should understand what a Type II DMF actually contains and how FDA reviews it during ANDA cycles. The guide to WHO-GMP, DMF and CEP compliance for Indian API manufacturers covers the DMF filing framework and the FDA review process.
3. FDA Import Alert Impact on Supply Availability
FDA import alerts targeting specific Indian or Chinese API facilities remove those facilities from US supply eligibility until the import alert is lifted. Between 2020 and 2025, multiple API facilities received import alerts related to data integrity findings or cGMP compliance issues, each removing supply capacity from the US Furosemide API market until remediation was completed. The residual supply is redistributed across the qualified supplier pool, producing short-term pricing pressure that resolves as new capacity is qualified or as import-alert facilities complete remediation. US buyers should factor this supply concentration risk into supplier qualification decisions, favouring facilities with clean multi-year inspection histories.
4. Raw Material and Key Starting Material Supply
Furosemide synthesis depends on specific key starting materials including 4-chloro-2-aminobenzoic acid and furfurylamine, historically sourced predominantly from Chinese chemical suppliers. Disruptions to KSM supply from China (regulatory action against Chinese chemical producers, geopolitical trade tensions, or logistics disruption) propagate into Furosemide API pricing as manufacturers absorb higher KSM costs or seek alternative sources. India's Production Linked Incentive (PLI) scheme, launched in 2020, has funded domestic KSM production capacity for critical drug intermediates, gradually reducing Indian API manufacturers' dependence on Chinese KSMs and stabilising downstream API pricing.
5. Order Volume and Annual Commitment Structure
Per-kilogram Furosemide API pricing for US buyers varies significantly with order volume and commercial structure. Spot orders at MOQ levels (typically 25 kg to 100 kg for first-time buyers) carry higher per-kilogram pricing than commercial-scale orders at 500 kg to 1,000 kg. Annual volume commitment arrangements - where a US buyer commits to a defined annual purchase volume in exchange for fixed pricing for the commitment period - typically achieve pricing 8 to 15 percent below spot pricing for equivalent volumes.
6. Freight and Logistics Cost Component
Sea freight from Indian ports (Mundra, Nhava Sheva) to US East Coast (New York, Norfolk, Savannah) or West Coast (Los Angeles, Long Beach) ports adds a per-kilogram freight cost that has been highly variable across 2020 to 2025. Sea freight rates on the India-US route spiked significantly during 2021 to 2022 pandemic disruption and have subsequently normalised, though rates remain more volatile than pre-2020 levels. Air freight for urgent shipments adds a per-kilogram premium, generally reserved for reference standards or emergency bridging supply rather than commercial bulk shipments.
US Furosemide API Pricing: What to Expect in 2026
The direction of US Furosemide API pricing in 2026 reflects three concurrent trends. First, the ongoing shift of US API sourcing from Chinese to Indian suppliers is broadly complete for Furosemide, with Indian manufacturers holding the majority of active US DMFs for the molecule. This shift has stabilised pricing at levels reflecting Indian manufacturing costs plus the DMF compliance premium. Second, FDA regulatory scrutiny of API facilities continues to intensify, with data integrity, ICH M7 genotoxic impurity assessment, and continued process verification programme depth all under increased review focus. Suppliers with mature quality systems are increasingly differentiated from suppliers whose systems appear compliant on paper but do not withstand deep FDA scrutiny.
Third, US ANDA holders are increasingly requiring their API suppliers to provide extensive regulatory support documentation beyond the basic DMF: named ICH Q3A impurity profiles, ICH M7 assessments for all synthesis-route genotoxic impurities, and stability data covering the specific pharmacopoeial grade and re-test period claimed in the DMF. Suppliers who can meet these documentation depth requirements without additional cost or delay typically achieve preferred supplier status with US ANDA holders, capturing volume without competing purely on per-kilogram price.
US procurement teams applying a structured supplier evaluation framework across a shortlist of DMF-filed Indian Furosemide API manufacturers can systematically score quality documentation depth, regulatory standing, and technical responsiveness alongside per-kilogram pricing. The Furosemide API supplier evaluation framework provides a practical scoring template for this comparative analysis.
Comparing US Furosemide API Sources: A Framework, Not a Ranking
Published pricing comparisons for Furosemide API from specific manufacturers are not typically available in the public domain, as commercial API pricing is negotiated bilaterally between buyer and supplier under confidentiality provisions. What US buyers can do systematically is compare the value composition of quotes from qualified suppliers, understanding what each quote actually delivers alongside the per-kilogram number.
| Comparison Dimension | Higher-Value Quote Includes | Lower-Value Quote Typically Excludes |
| Regulatory Documentation | Full DMF reference letter, ICH Q3A profile, ICH Q1A stability | DMF number only; documentation on request |
| Response Time | 1-2 business days for enquiries | >5 business days for basic questions |
| Technical Support | Direct dialogue with QA/regulatory team | Sales team relay only |
| FDA Inspection History | Clean EIR record, no active import alerts | Recent Form 483 without CAPA closure |
| Batch Consistency Data | Multi-batch particle size, XRPD, impurity data | Single batch reference only |
| Delivery Terms | Clear DDP or FOB with all documentation | Basic FOB without complete docs |
The lowest per-kilogram Furosemide API quote in a US procurement exercise frequently corresponds to the highest total-cost-of-ownership over the supply relationship lifecycle. A supplier whose documentation is incomplete requires the ANDA holder's regulatory team to invest additional hours reconciling gaps, delaying ANDA supplement approvals. A supplier whose technical team is slow to respond creates operational friction that compounds across every quality event or batch investigation. A supplier whose FDA inspection record has open Form 483 observations creates ANDA-level regulatory risk that is not visible in the API pricing.
Kodel Life: US-Ready Furosemide API Supply
Kodel Life manufactures Furosemide API at the Morbi, Gujarat facility under ISO 9001:2015 Quality Management System certification and FDA-compliant cGMP manufacturing practices. The Morbi facility supplies Furosemide API to 21 countries across 5 continents, with regulatory documentation depth suitable for US ANDA support including DMF reference letters, ICH Q3A named impurity profiles, ICH M7 assessments for glycidyl ether epoxide intermediate purge, and ICH Q1A stability data with XRPD polymorph monitoring.
For US pharmaceutical procurement teams seeking a Furosemide API supplier who combines competitive Indian-market pricing with US-ready regulatory documentation and one to two business day technical response times, Kodel Life provides direct-to-manufacturer engagement without intermediaries. Contact info@kodellife.com or call +91 75023 33335 to request a USA-specific commercial quotation with delivery terms, MOQ, and documentation scope confirmed for your specific ANDA support requirement.
US regulatory affairs teams preparing Furosemide API drug substance sections for ANDA supplements or new ANDA filings benefit from understanding the underlying manufacturing process and cGMP controls that support the DMF submission. The Furosemide API manufacturing process and cGMP controls guide covers synthesis route, in-process controls, and impurity qualification that apply to Furosemide API from any DMF-filed Indian manufacturer serving the US market.
Procurement Guidance for US Furosemide API Buyers
Verify DMF Status Independently
Never accept a supplier's DMF claim without independent verification. Search accessdata.fda.gov for the Drug Master File database, filter for the manufacturer's registered entity name, and confirm the DMF is active for Furosemide with the DMF number matching the supplier's reference letter. A DMF listed as 'inactive' or 'closed' cannot be referenced in an ANDA filing regardless of what the supplier's documentation implies.
Request a Complete Regulatory Documentation Package Before Committing
Before signing a first commercial supply agreement, request the full regulatory documentation package from the supplier: DMF reference letter with active DMF number, WHO-GMP or EU-GMP certificate copy, ICH Q3A named impurity profile document, ICH M7 assessment for genotoxic impurities in the synthesis route, ICH Q1A stability data summary with numeric results at each time point, and sample COAs from three consecutive commercial batches. A supplier who cannot produce this complete pack within five business days is signalling documentation readiness gaps that will surface at every ANDA supplement filing.
Confirm FDA Inspection History
Check the FDA establishment search database for the manufacturing facility's inspection history. Look for the date of the most recent inspection, the classification (NAI = No Action Indicated, VAI = Voluntary Action Indicated, OAI = Official Action Indicated), and any active import alerts or Warning Letters. A facility with a recent NAI classification and no outstanding regulatory actions is the baseline for US supply eligibility.
Structure Annual Volume Commitments for Predictable Pricing
For US ANDA holders with predictable annual Furosemide API requirements above 1,000 kg per year, negotiating an annual volume commitment agreement with the primary supplier locks in pricing, secures dedicated batch scheduling priority, and reduces per-kilogram cost by 8 to 15 percent compared to spot ordering. The commitment structure also supports supply continuity planning by pre-scheduling batches across the year rather than reacting to individual purchase orders.
US buyers importing Furosemide API from Indian manufacturers should also confirm the export documentation and customs preparation workflow at the Indian origin end of the supply chain. The Furosemide API export from India documentation guide covers ITCHS classification, shipping bill preparation, and destination-market documentation packs applicable to US-bound shipments through New York, Norfolk, or Los Angeles ports of entry.
Pricing Is a Function of Value, Not Just Cost
Furosemide API pricing in the USA in 2026 reflects a mature market where the qualified supplier pool is smaller than the global manufacturer pool but larger than five years ago, where Indian manufacturers dominate the DMF-filed supplier landscape, and where per-kilogram pricing has stabilised around Indian manufacturing costs plus a DMF compliance premium. US buyers who focus their procurement analysis on total value — regulatory documentation depth, technical responsiveness, FDA inspection history, batch consistency evidence — rather than exclusively on per-kilogram price achieve stronger long-term supply relationships and lower total cost of ownership across the supply lifecycle.
Kodel Life combines competitive Indian-market Furosemide API pricing with US-ready regulatory documentation, direct-to-manufacturer engagement, and one to two business day response times. Contact info@kodellife.com or call +91 75023 33335 for USA-specific pricing.
